BCAX Stock Analysis: Buy, Sell, or Hold?
BCAX - Bicara Therapeutics Inc. Common Stock
$16.80
-0.11 (-0.65%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 26, 2026
Get Alerted When BCAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BCAX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BCAX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BCAX is currently trading at $16.80, which is considered fair relative to its 30-day fair value range of $16.36 to $17.39.
Technical Outlook: Technically, BCAX is in a uptrend. Immediate support is located at $15.73, while resistance sits at $18.24.
Market Sentiment: BCAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.80 (+83.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BCAX is in a uptrend. Immediate support is located at $15.73, while resistance sits at $18.24.
Market Sentiment: BCAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.80 (+83.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$16.36 -
$17.39
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 83.3% below Wall St target ($30.80)
Fair Price Analysis
30-Day Fair Range
$16.36 -
$17.39
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$1.68
(10.0%)
Support & Resistance Levels
Support Level
$15.73
Resistance Level
$18.24
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-5.67
Wall Street Target
$30.80
(+83.3%)
Last updated: February 01, 2026 7:53 PM ET
Data refreshes hourly during market hours. Next update: 8:53 PM
Data refreshes hourly during market hours. Next update: 8:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Claire Mazumdar
SELL
13289 shares
2025-10-15
Ryan Cohlhepp
SELL
12500 shares
2025-10-15
Claire Mazumdar
SELL
11445 shares
2025-10-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 59 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
